I

n 2001, a modified World Trade Organization agreement ushered in a new era of access to medicines by giving countries the right to sidestep drug makers that charged unaffordable prices. But since then, the number of instances in which a country has pursued any of the sanctioned measures was believed to be rather small, especially since the pharmaceutical industry has often raised strenuous objections.

Now, though, a new analysis finds that 89 countries made extensive use of the trade agreement provisions between 2001 and 2016, a fact that was not previously reported. In all, there were 176 instances involving medicines used to treat 14 different diseases, and 87 percent were implemented, according to the analysis, which was published in the Bulletin of the World Health Organization.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy